But another study demonstrated that AGO2 could physically interact with RAS (HRAS, NRAS, and KRAS) and activated KRAS (GTPase) signaling to promote lung cancer progression (53), which was consistent with our results that AGO2 may act as a tumor promoter in LUAD patients and may be a potential target for treatment. Here, AGO2 is linked to lung carcinoma.